Creatinine Assay Kits Market : New Trends, Opportunities and Key Players

Posted by Rahul G on July 14th, 2021

The global creatinine assay kits market is expected to reach USD 245.4 Million by 2022 from USD 189.6 Million in 2017, at a CAGR of 5.3%. The growth of this market is mainly driven by the increasing incidence of renal disorders, growing incidence of other chronic disorders impacting renal function, growing awareness and adoption of preventive healthcare, favourable government initiatives to promote renal health, rapid growth in the geriatric population, and advancements in biomedical research pertaining to kidney disorders and availability of funding.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=73499229

This report segments the market on the basis of type, type of sample, and region. By type, the market is segmented into Jaffe’s kinetic test kits, Creatinine-PAP test kits, and ELISA test kits. In 2017, the Jaffe’s kinetic test kits segment accounted for the largest share of the market, since it is the oldest and most conventional method for creatinine measurement. Additionally, wide product availability and cost-effectiveness of these kits are some of the other major factors responsible for the large share of this segment.

Based on type of sample, the market is segmented into blood/serum, urine, and other samples. The urine samples segment accounted for the largest share of the market in 2017, owing to ease of sample availability and non-invasive method of sample collection. The blood/serum segment is expected to witness the fastest growth over the forecast period, as it ensures greater result accuracy.

In 2017, North America dominated the market followed by Europe. Asia is expected to grow at the highest CAGR during the forecast period. This can be attributed to factors such as the large population base in Asian countries, growing geriatric population, growing prevalence of CKD, rising awareness towards preventive healthcare, improving healthcare infrastructure, and growing focus of market players on addressing demands in these countries. The increasing prevalence of infectious diseases and metabolic syndromes in this region is resulting in the high and regular prescription for metabolic tests.

On the other hand, limited usage of creatinine assay kits in IVD, identification of novel renal dysfunction biomarkers, and frequently changing regulatory policies are expected to restrain the growth of this market to a certain extent.

The creatinine assay kits market is highly fragmented with the presence of several small and big players. Prominent players in this market include Thermo Fisher Scientific (US), Merck (Germany), Abbott Laboratories (US), Abcam (UK), Quidel (US), Enzo Life Sciences (US), Cayman Chemical (US), Cell Biolabs (US), Genway Biotech (US), BioAssay Systems (US), Wako Pure Chemical Industries (Japan), Tulip Diagnostics (India), BioVision (US), and Arbor Assays (US).